DelveInsight estimated an overall Multiple myeloma incidence of 85,971 cases in the eight major markets (i.e the United States, EU5, Japan, and China). Among the 8MM, the United States accounted for the highest Multiple Myeloma incident cases, and as per the estimates, the incidence cases are expected to increase during the forecast period 2020-30 steadily. It has observed that men are more likely to get diagnosed with Multiple myeloma than women in 8MM.
In the 8MM, the Multiple myeloma therapeutics market size was found to be USD 14,111 million in 2017, which is expected to increase during the study period (2017–2030).
Some of the key companies involved in developing therapies for Multiple Myeloma includes GlaxoSmithKline, Bristol-Myers Squibb, AbbVie, Roche, Janssen Research & Development, Merck Sharp & Dohme Corp., Pfizer, Takeda, Amgen, AstraZeneca, and many others.
For more details on Multiple Myeloma Market, visit: https://www.delveinsight.com/blog/multiple-myeloma-market/